MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-31-2025
NeuroMetrix Revenue 2011-2026 | NURO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue NeuroMetrix
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.03 M | 5.9 M | 8.26 M | 8.25 M | 7.38 M | 9.27 M | 16.1 M | 17.1 M | 12 M | 7.3 M | 5.51 M | 5.28 M | 7.58 M | 10.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.1 M | 3.03 M | 8.81 M |
Quarterly Revenue NeuroMetrix
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 587 K | 769 K | 1.09 M | - | 1.2 M | 1.66 M | 1.72 M | - | 1.97 M | 2.14 M | 2.3 M | - | 2.06 M | 2.21 M | 2.16 M | - | 2.04 M | 1.36 M | 2.17 M | - | 2.09 M | 2.35 M | 3.12 M | - | 3.67 M | 3.75 M | 4.94 M | - | 3.55 M | 4.31 M | 4.31 M | - | 3.39 M | 2.65 M | 2.28 M | - | 2.05 M | 1.22 M | 1.28 M | - | 1.43 M | 1.34 M | 1.33 M | - | 1.31 M | 1.16 M | 1.4 M | - | 1.76 M | 2.21 M | 2.08 M | - | 2.56 M | 2.57 M | 2.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.94 M | 587 K | 2.2 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
2.75 B | $ 20.66 | 1.27 % | $ 10.5 B | USA |
 |
Becton, Dickinson and Company
BDX
|
21.8 B | $ 205.09 | 1.16 % | $ 59 B | USA |
 |
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
17.9 M | $ 8.15 | -7.6 % | $ 164 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | USA |
 |
Alcon
ALC
|
9.91 B | $ 80.67 | -0.38 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
465 M | $ 42.59 | 1.96 % | $ 2 B | USA |
 |
electroCore
ECOR
|
16 M | $ 5.15 | 6.19 % | $ 28.4 K | USA |
 |
Haemonetics Corporation
HAE
|
1.36 B | $ 84.98 | 2.36 % | $ 4.28 B | USA |
 |
AngioDynamics
ANGO
|
292 M | $ 10.02 | -8.29 % | $ 409 M | USA |
 |
Harvard Bioscience
HBIO
|
112 M | $ 0.66 | -1.92 % | $ 28 M | USA |
 |
The Cooper Companies
COO
|
4.09 B | $ 83.38 | -0.63 % | $ 16.6 B | USA |
 |
ICU Medical
ICUI
|
2.38 B | $ 152.88 | 1.7 % | $ 3.73 B | USA |
 |
Glaukos Corporation
GKOS
|
315 M | $ 114.49 | 0.43 % | $ 5.55 B | USA |
 |
InfuSystem Holdings
INFU
|
110 M | $ 8.9 | -0.11 % | $ 184 M | USA |
 |
iRhythm Technologies
IRTC
|
592 M | $ 188.16 | 0.41 % | $ 5.87 B | USA |
 |
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | USA |
 |
Repro Med Systems
KRMD
|
28.5 M | $ 5.79 | 3.02 % | $ 264 M | USA |
 |
LeMaitre Vascular
LMAT
|
220 M | $ 85.05 | 1.55 % | $ 1.91 B | USA |
 |
Masimo Corporation
MASI
|
2.09 B | $ 138.18 | 0.8 % | $ 7.36 B | USA |
 |
Intuitive Surgical
ISRG
|
8.35 B | $ 586.15 | -1.03 % | $ 208 B | USA |
 |
Merit Medical Systems
MMSI
|
1.36 B | $ 93.33 | 1.83 % | $ 5.43 B | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 2.19 | 3.55 % | $ 22.3 M |  Israel |
 |
Nephros
NEPH
|
14.2 M | $ 5.07 | -1.74 % | $ 52.7 M | USA |
 |
Milestone Scientific
MLSS
|
8.63 M | $ 0.29 | 2.24 % | $ 23.1 M | USA |
 |
Envista Holdings Corporation
NVST
|
2.51 B | $ 23.52 | 2.53 % | $ 4.05 B | USA |
 |
OraSure Technologies
OSUR
|
186 M | $ 2.65 | 5.38 % | $ 197 M | USA |
 |
Pro-Dex
PDEX
|
66.6 M | $ 41.83 | 4.47 % | $ 138 M | USA |
 |
Predictive Oncology
POAI
|
1.62 M | $ 6.85 | 3.24 % | $ 37.4 M | USA |
 |
Pulse Biosciences
PLSE
|
700 K | $ 14.71 | -3.26 % | $ 707 M | USA |
 |
Repligen Corporation
RGEN
|
632 M | $ 165.12 | -2.32 % | $ 9.2 M | USA |
 |
ResMed
RMD
|
3.58 B | $ 250.85 | 1.07 % | $ 36.6 B | USA |
 |
BioLife Solutions
BLFS
|
82.3 M | $ 24.91 | -1.97 % | $ 1.15 B | USA |
 |
STERIS plc
STE
|
5.46 B | $ 260.64 | 0.52 % | $ 25.7 B | USA |
 |
Stereotaxis
STXS
|
26.8 M | $ 2.57 | -1.35 % | $ 207 M | USA |
 |
Retractable Technologies
RVP
|
33 M | $ 0.76 | -0.53 % | $ 22.8 M | USA |
 |
STAAR Surgical Company
STAA
|
314 M | $ 22.43 | 1.08 % | $ 1.1 B | USA |
 |
Utah Medical Products
UTMD
|
12.3 M | $ 58.5 | 1.39 % | $ 212 M | USA |
 |
Teleflex Incorporated
TFX
|
3.05 B | $ 110.0 | -13.07 % | $ 5.15 B | USA |
 |
West Pharmaceutical Services
WST
|
2.89 B | $ 274.0 | -1.62 % | $ 20 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
3.79 B | $ 12.53 | 1.25 % | $ 2.55 B | USA |